Introduction {#sec1_1}
============

Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition comprised of several disorders that can involve one or multiple organs and appears with particular histopathologic, serologic, and clinical features \[[@B1], [@B2]\]. The affected organs include the pancreas, gall bladder, liver, thyroid, lungs, kidneys, skin, cranial nerves, retroperitoneum, prostate, pituitary, and salivary and lacrimal glands. The hallmarks of IgG4-RD are swelling and enlargement of the affected organ(s) with characteristic lymphoplasmacytic infiltrations composed of IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis, mild to moderate eosinophilia, and remarkably high serum IgG and IgG4 \[[@B3]\].

Autoimmune pancreatitis (AIP) is a rare disorder of autoimmune etiology, which is associated with characteristic clinical, histologic, and morphologic findings \[[@B4]\]. Type 1 AIP is the prototypical form of IgG4-RD and can be associated with involvement of multiple organs \[[@B5], [@B6]\]. The most common symptoms are obstructive jaundice, abdominal pain, and weight loss. New-onset diabetes mellitus (DM) may also occur. Type 2 AIP is a primary pancreatic disorder without relation to IgG4 \[[@B7]\].

Kidneys involvement with tubulointerstitial nephritis (TIN), as part of the IgG4-RD, was first described in 2004 \[[@B8]\]. It is characterized by interstitial infiltration of IgG4-positive plasma cells, IgG deposits along the tubular basement membranes, and fibrosis \[[@B9], [@B10]\]. IgG4-related membranous nephropathy (MN) is much less common than IgG4-related TIN, and these 2 pathologies usually occur together \[[@B11]\].

Here, we report a patient who presented with deregulation of preexisting type 2 DM as the first manifestation of AIP. The patient\'s medical history included "idiopathic" MN 3 years earlier, which was finally attributed to IgG4-RD after being diagnosed with type 1 AIP.

Case Presentation {#sec1_2}
=================

A 70-year-old male was admitted to our hospital due to abdominal pain localized in the epigastrium, weight loss of 10 kg over the previous 2 months, and deregulation of preexisting type 2 DM that necessitated more aggressive antidiabetic therapy with insulin during the preceding 6 months. He had a history of MN successfully treated with methylprednisolone and cyclophosphamide 3 years ago, hypertension, dyslipidemia, and benign prostate hyperplasia. Physical examination revealed only epigastric tenderness. Laboratory tests showed an elevated erythrocyte sedimentation rate of 45 mm/1 h (normal range \[NR\] 0--20 mm/1 h), normochromic, normocytic anemia (hemoglobin at 12.3 g/dL, NR 13.4--17.4 g/dL) and increased glycated hemoglobin (HbA1c) at 8%. Hepatic and pancreatic enzymes, arterial pH, and kidney function were all normal. A contrast-enhanced abdominal computed tomography (CT) revealed enlargement and edema of the pancreatic body and tail along with decreased density of the pancreatic parenchyma and inflammation of the peripancreatic fat tissue; findings compatible with interstitial pancreatitis. A significant narrowing of the pancreatic duct at the head of the pancreas was also noted. A magnetic resonance imaging (MRI) of the abdomen and an MR cholangiopancreatography confirmed the diagnosis of pancreatitis and excluded the presence of gallstones or choledocholithiasis. Notably, the above-mentioned findings were not present in an abdominal CT performed 3 years ago when MN was diagnosed. The patient was assessed with endoscopic ultrasound (EUS) which revealed findings suggestive of chronic pancreatitis with 1 major B and 3 minor features, based upon the Rosemont classification \[[@B12]\]. More specifically, there was a diffusely enlarged pancreatic gland with poor echotexture, lobularity with "honeycombing," stranding, hyperechoic foci without shadowing, and a normal main pancreatic duct with dilated side branches. A fine-needle aspiration biopsy was performed. Cytological examination demonstrated low-grade dysplasia of the ductal epithelium with no evidence of malignancy. The patient underwent a second EUS examination, and new tissue specimens were obtained for histological examination. Immunohistochemistry revealed lymphoplasmocytic infiltration of the gland with IgG4-positive plasmocytes. Further serological findings showed increased serum IgG4 levels (1,220 mg/dL, NR 8--140 mg/dL), while antinuclear antibodies and rheumatoid factor were not present. Based on the revised HISORT (Histology, Imaging, Serology, other Organ involvement and Response to Therapy) criteria \[[@B5]\], the patient was diagnosed with type 1 AIP, and oral prednisolone treatment was initiated at a dose of 40 mg daily for 4 weeks followed by a tapering of 5 mg per week. Two weeks later, the abdominal pain had subsided, and fasting blood glucose levels had decreased. Ten weeks after initiation of prednisolone, the abnormal CT findings had significantly improved and serum IgG4 levels had decreased at 394 mg/dL. Moreover, HbA1c declined at 6.5%, insulin was withheld, and oral antidiabetic drugs were restarted.

The renal biopsy was reevaluated, and immunohistochemistry to detect ΙgG/IgG4 and phospholipase A2 receptor (PLA2R) was performed. Immunohistochemistry demonstrated a strong, diffuse, and global staining for both IgG and IgG4 along the walls of the glomerular capillaries with a fine granular pattern (Fig. [1a--c](#F1){ref-type="fig"}), whereas PLA2R was negative (Fig. [1d](#F1){ref-type="fig"}). The interstitial tissue did not show infiltration by lymphocytes, plasmocytes, or any other inflammatory cells (Fig. [1e](#F1){ref-type="fig"}), and so, no staining for IgG or IgG4 was observed in the interstitium (Fig. [1f](#F1){ref-type="fig"}). No staining along the tubular basement membranes was found (Fig. [1f](#F1){ref-type="fig"}). Of note, no morphological signs of secondary membranous glomerulopathy, for instance increased mesangial cellularity, were observed (Fig. [1g, h](#F1){ref-type="fig"}). A serum sample frozen at the time of kidney biopsy was retrospectively examined for the presence of anti-PLAR antibodies by the immunofluorescence method (Euroimmun AG, Germany) and tested negative. Despite the presence of unselective proteinuria at the time of serum sampling, IgG4 levels were slightly high (at 186 mg/dL), implying the presence of IgG4-RD from the outset.

Discussion {#sec1_3}
==========

IgG4-RD is a novel immune-mediated condition that can present with multi-organ involvement. IgG4-RD has also been observed in several subjects previously diagnosed with conditions that were regarded as organ-specific entities. We report a patient who presented with exacerbation of DM as the first manifestation of AIP. According to the literature, DM is present in 70% of all type 1 AIP cases \[[@B13]\]. Importantly, AIP-induced DM improves with corticosteroid treatment \[[@B14]\]. Corticosteroids recover pancreatic endocrine function by suppression of lymphoplasmacytic infiltration and cytokine production \[[@B14]\]. A unique feature of the presented case is that our patient had formerly been diagnosed with MN as a separate, organ-specific entity since there was no evidence of extrarenal manifestations suggestive of IgG4-RD at that time. Three years later, the diagnosis of type 1 AIP led to the diagnosis of IgG4-RD, raising the possibility that the earlier glomerulopathy had been part of the systemic disease. The association between IgG4-RD and MN is not well established. The most common renal manifestation of IgG4-RD is plasma cell-rich TIN with "storiform" fibrosis. In 2013, Alexander et al. \[[@B15]\] demonstrated that MN can be part of IgG4-related kidney disease in 7% of patients, usually in association with concurrent TIN. Given that IgG4 is the main subtype observed in the immunodeposits of primary MN, it is quite difficult to connect a MN with an underlying IgG4-RD, if there is no appropriate clinical history suggesting an IgG4-RD, especially in the absence of TIN. In secondary forms of MN, such IgG4 antibodies are absent or less prevalent \[[@B16]\], with the exception (by definition) of MN in the context of IgG4-RD. When IgG4-RD is diagnosed upon other organ(s) involvement, then suspicion should be raised that MN might be part of this syndrome, as rare cases of primary MN have been described in the context of IgG4-RD \[[@B17], [@B18], [@B19], [@B20]\]. The differential diagnosis between primary and secondary MN in a patient with known IgG4-RD is mainly based on the presence or absence of other markers, such as PLA2R. In our case, IgG4 was positive in the immune deposits, as expected either in a primary MN or in a MN secondary to IgG4-RD. However, the retrospectively performed PLA2R analysis was negative (both anti-PLAR antibodies in serum and PLAR antigen in glomeruli), indicating a secondary etiology and, in this case, a MN in the context of an IgG4-RD. Another interesting point in our case is that the diagnosis of IgG4-RD was established after the diagnosis of MN, reminiscent of cases where MN can precede the discovery of a neoplastic disease. The time frame for the appearance of the manifestations of IgG4-RD from different organs can be very wide. For instance, a patient reported by Cravedi et al. \[[@B19]\] with IgG4-related MN was diagnosed 3 years after AIP, similar to our patient. So, in cases of IgG4-positive/PLA2R-negative MN associated with other IgG4-RD manifestations, the possibility of a MN in the context of IgG4-RD should be kept in mind to guarantee the subsequent appropriate investigation and follow-up of the patients.

Conclusion {#sec1_4}
==========

We bring this case to the attention of physicians for 2 reasons. First, our case suggests that type 1 AIP should always be considered as part of the differential diagnosis in patients presenting with unexplained exacerbation of DM and a thorough workup should be performed in order to identify an existing pancreatic disorder. Secondly, isolated IgG4-positive/PLA2R-negative MN without TIN, although rare, can be a prodrome of IgG4-RD, reminiscent of MN secondary to neoplasms.
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![Kidney biopsy findings. **a** Strong global granular IgG staining along the capillary walls; IgG, ×400. **b**, **c** Strong global fine granular IgG4 staining along the capillary walls; IgG4, ×400. **d** Negative PLA2R immunohistochemical staining; ×200. **e** Membranous nephropathy without tubulointerstitial nephritis; Masson, ×100. **f** Low-power magnification (×40) showing diffuse IgG4 glomerular staining with no staining in the interstitium. **g** Membranous nephropathy without morphological signs of secondary etiology (without mesangial cellularity); Masson, ×400. **h** Membranous nephropathy without morphological signs of secondary etiology (without mesangial cellularity); Silver, ×400.](cnd-0009-0085-g01){#F1}
